OSI Pharmaceuticals Inc. Presents at BioTrinity 2010, Apr-12-2010 through Apr-14-2010. Venue: Newbury Racecourse plc, The Racecourse, Newbury, Berkshire RG14 7NZ, United Kingdom.

Astellas US Holding Inc. filed a lawsuit in the Delaware Court of Chancery against OSI Pharmaceuticals Inc. and its directors seeking, among other things, declaratory and injunctive relief enjoining OSI and its directors from engaging in any action or inaction, including applying OSI's "poison pill" rights plan, that has the effect of improperly impeding, thwarting, frustrating or interfering with the tender offer in a manner inconsistent with the directors' fiduciary duties. The Astellas tender offer represents a significant premium of over 40% to OSI's closing share price of $37.02 on February 26, 2010, a 53% premium to its three-month average of $34.01 per share and a 31% premium to its 52-week high of $39.66 per share. The offer is not conditioned on financing. The offer is conditioned on there being validly tendered and not withdrawn at least a majority of the total number of OSI shares outstanding on a fully diluted basis, OSI's board of directors redeeming or invalidating its "poison pill" shareholder rights plan and receipt of regulatory approvals and customary closing conditions as described in the Offer to Purchase.

OSI Pharmaceuticals Inc. expected to Report Q1 2010 Results on April 26, 2010. This event was calculated by Capital IQ (Created on February 23, 2010).